Deploying Nu.Q® Capture as the first blood sample
processing step could potentially:
Enhance the sensitivity of subsequent Nu.Q® immunoassays for diagnosing and monitoring different types of disease using our proprietary Nucleosomics™ platform.
Aid the development of improved diagnostic DNA sequencing methods.
Serve as a quality control tool to reduce the rate of clinical test failure, saving time that is especially valuable for people whose test results are being used to inform their treatment.
Aid the discovery of new biomarkers.